SangminLeeMD

PubMed

• 446 citations
  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
  Andrew H. Wei, Stephen A. Strickland, Jing Zhou Hou, Walter Fiedler, Tara L. Lin
  Journal of Clinical Oncology. 2019-03-20
• 377 citations
  Somatic mutations precede acute myeloid leukemia years before diagnosis.
  Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang
  Nature Medicine. 2018-07-01
• 46 citations
  Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
  Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee
  The Lancet. Haematology. 2023-01-01

Journal Articles

• Somatic Mutations Precede Acute Myeloid Leukemia Years Before Diagnosis  
  Sangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature

Abstracts/Posters

• Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CPX-351 As First Intensive Therapy for Elderly Patients with AML
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
  Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant? 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all